Haemorrhages and Thromboembolic Venous Disease of the Postpartum

University Hospital, Brest20,241 enrolled

Overview

The aim of this study is to evaluate the frequencey and the determinants of postpartum major complications (hemorrhage and thrombosis) up to 3 months after delivery in the maternity hospitals of Finistère (Bretagne - France)

This is an analytical observational prospective multicenter cohort study , conducted on all the maternity hospitals in Finistère (Bretagne - France), with a biological collection. This protocol allows to study all women at risk of PPH (Postpartum Hemorrhage) and postpartum venous thromboembolic disease, including maternity level 1-3 without case selection. The prospective nature of the study should provide a more detailed analysis of exposures in this particular population of women (risk factors related to the field, childbirth, the postpartum events ...). The events of interest were PPH and venous thromboembolic disease.

Study Type

OBSERVATIONAL

Enrollment

20,241

Conditions

Postpartum Hemorrhage Venous Thromboembolism

Eligibility

Sex: FEMALEMin age: 16 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Any woman giving birth and supported in one of Gynaecology Obstetrics services of a maternity Finistere. * Women ≥ 16 at the time of the collection of non-opposition. * For minor patients: understanding the patient and at least one parent. * All births ≥ 15 weeks gestation. Exclusion Criteria: * Home Birth * Expressed opposition to participation in this study. * Childbirth under X. * Parent (s) uninformed of the pregnancy of their child.

Locations (6)

CH de Carhaix

Carhaix-Plouguer, Finistère, France

CHRU de Brest - Service de Gynécologie-obstétrique

Brest, France

Clinique Keraudren

Brest, France

CH de Landerneau

Landerneau, France

Outcomes

Primary Outcomes

Postpartum Hemorrhage

Volume of blood loss up to 48 hours after delivery and / or weight compresses collected at delivery, and / or diagnosis of the clinician

Time frame: 2 days

Symptomatic thromboembolic events

Time frame: 3 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.